These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 28275038)

  • 1. An Expanding Role for Immunotherapy in Colorectal Cancer.
    Bever KM; Le DT
    J Natl Compr Canc Netw; 2017 Mar; 15(3):401-410. PubMed ID: 28275038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
    Quiroga D; Lyerly HK; Morse MA
    Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
    Kather JN; Halama N; Jaeger D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.
    Kreidieh M; Mukherji D; Temraz S; Shamseddine A
    Biomed Res Int; 2020; 2020():9037217. PubMed ID: 32090113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in colorectal cancer: rationale, challenges and potential.
    Ganesh K; Stadler ZK; Cercek A; Mendelsohn RB; Shia J; Segal NH; Diaz LA
    Nat Rev Gastroenterol Hepatol; 2019 Jun; 16(6):361-375. PubMed ID: 30886395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results and challenges of immune checkpoint inhibitors in colorectal cancer.
    Emambux S; Tachon G; Junca A; Tougeron D
    Expert Opin Biol Ther; 2018 May; 18(5):561-573. PubMed ID: 29471676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in colorectal cancer.
    Agarwal P; Le DT; Boland PM
    Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.
    Bai Z; Zhou Y; Ye Z; Xiong J; Lan H; Wang F
    Front Immunol; 2021; 12():808964. PubMed ID: 35095898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the Verge: Immunotherapy for Colorectal Carcinoma.
    Oh DY; Venook AP; Fong L
    J Natl Compr Canc Netw; 2015 Aug; 13(8):970-8. PubMed ID: 26285242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.
    Link JT; Overman MJ
    Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancing Immunotherapy in Metastatic Breast Cancer.
    Mansour M; Teo ZL; Luen SJ; Loi S
    Curr Treat Options Oncol; 2017 Jun; 18(6):35. PubMed ID: 28534250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying and clinically validating biomarkers for immunotherapy in colorectal cancer.
    Yeh YS; Tsai HL; Chen PJ; Chen YC; Su WC; Chang TK; Huang CW; Wang JY
    Expert Rev Mol Diagn; 2023 Mar; 23(3):231-241. PubMed ID: 36908268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in Colorectal Cancer - Finding the Achilles' Heel.
    Park R; Saeed A
    NEJM Evid; 2024 Jun; 3(6):EVIDra2300353. PubMed ID: 38804784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on the use of immunotherapy in patients with colorectal cancer.
    Nguyen M; Tipping Smith S; Lam M; Liow E; Davies A; Prenen H; Segelov E
    Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):291-304. PubMed ID: 33138649
    [No Abstract]   [Full Text] [Related]  

  • 18. Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials.
    Advani S; Kopetz S
    J Surg Oncol; 2019 Apr; 119(5):642-652. PubMed ID: 30852840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The colorectal cancer immune microenvironment and approach to immunotherapies.
    Koi M; Carethers JM
    Future Oncol; 2017 Aug; 13(18):1633-1647. PubMed ID: 28829193
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune Checkpoint Therapies in Prostate Cancer.
    Goswami S; Aparicio A; Subudhi SK
    Cancer J; 2016; 22(2):117-20. PubMed ID: 27111907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.